gsk201204196k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending April 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--
 
 





 

 
 
 
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibility or Connected Persons
 
 
The Administrators of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan (the Plan) notified the Company and the under-mentioned persons on 18 April 2012 of an increase in their interests in American Depositary Shares (ADSs) at a price of $44.74 per ADS following the re-investment of dividends paid to shareholders on 12 April 2012.
 
Mrs D P Connelly
Acquisition of 14.826 ADSs under the personal contribution element of the Plan.
   
 
 
 
Mr W C Louv
 
 
Notional increase of 15.143 ADSs under the matching element of the Plan (Company contribution).
 
Acquisition of 38.938 ADSs under the personal contribution element of the Plan.
 
Notional increase of 39.761 ADSs under the matching element of the Plan (Company contribution).
 
The afore-mentioned individuals have elected to participate in the Plan in respect of their 2010 bonus on a post-tax basis. The notional dividends accrued under the matching element will be paid out in proportion to the percentage of the participant's deferred annual bonus matching award holdings that will vest following the end of the relevant three year measurement period.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
 
V A Whyte
Company Secretary
 
19 April 2012
 
 
 

 


 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 19, 2012 
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc